Sialylation regulates galectin-3/ligand interplay during mammary tumour progression - a case of targeted uncloaking

International Journal of Developmental Biology

Volumn 55, Issue 7-9, 2011, Pages 823-834

  de Oliveira, Joana Tavares ^a   de Matos, Augusto José ^a   Santos, Ana L ^a   Pinto, Rita ^a   Gomes, Joana ^a   Hespanhol, Venceslau ^b   Chammas, Roger ^c   Aki, Manninen ^d   Bernardes, Emerson S ^a   Reis, Celso Albuquerque ^a   Rutteman, Gerard ^e   Gärtner, Fátima ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF OULU   (Finland)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Galectin 3; Galectin 3 ligand; Mammary tumour; Metastasis; Sialylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; MUCIN 1; SIALIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MEMBRANE; CELL SUBPOPULATION; CONTROLLED STUDY; DOG; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIALYLATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BINDING SITES; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; DOG DISEASES; DOGS; DOWN-REGULATION; FEEDBACK, PHYSIOLOGICAL; FEMALE; GALECTIN 3; IMMUNOHISTOCHEMISTRY; LIGANDS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MUCIN-1; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIALIC ACIDS; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 82555181297     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.113359jt     Document Type: Article

References (50)

1. AHMED, H., BANERJEE, P. P., VASTA, G. R. (2007). Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 358: 241-246.
2. BOCKHORN, M., JAIN, R. K., MUNN, L. L. (2007). Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8: 444-448.
3. BURGESS, A. W., CHO, H. S., EIGENBROT, C., FERGUSON, K. M., GARRETT, T. P., LEAHY, D. J., LEMMON, M. A., SLIWKOWSKI, M. X., WARD, C. W., YOKOYAMA, S. (2003). An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541-552.
4. CASTRONOVO, V., VAN DEN BRÛLE, F. A., JACKERS, P., CLAUSSE, N., LIU, F. T., GILLET, C., SOBEL, M. E. (1996). Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179: 43-48.
5. CHAMBERS, A. F., GROOM, A. C., MACDONALD, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
6. da COSTA, A., OLIVEIRA, J. T., GÄRTNER, F., KOHN, B., GRUBER, A. D., KLOPFLEISCH, R. (2010). Potential markers for detection of circulating canine mammary tumor cells in the peripheral blood. Vet J.
7. COUTO, J. R., TAYLOR, M. R., GODWIN, S. G., CERIANI, R. L., PETERSON, J. A. (1996). Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor-like domain. DNA Cell Biol 15: 281-286.
8. DALZIEL, M., HUANG, R.Y., DALL'OLIO, F., MORRIS, JR., TAYLOR-PAPADIMITRIOU, J., LAU, J.T. 2001. Mouse ST6Gal sialyltransferase gene expression during mammary gland lactation. Glycobiology 11: 407-412.
9. FRIEDRICHS, J., TORKKO, J. M., HELENIUS, J., TERÄVÄINEN, T. P., FÜLLEKRUG, J., MULLER, D. J., SIMONS, K., MANNINEN, A. (2007). Contributions of galectin-3 and-9 to epithelial cell adhesion analyzed by single cell force spectroscopy. J Biol Chem 282: 29375-29383.
10. GILLESPIE, W., PAULSON, J. C., KELM, S., PANG, M., BAUM, L. G. (1993). Regulation of alpha 2, 3-sialyltransferase expression correlates with conversion of peanut agglutinin (PNA)+ to PNA-phenotype in developing thymocytes. J Biol Chem 268: 3801-3804.
11. HIRABAYASHI, J., HASHIDATE, T., ARATA, Y., NISHI, N., NAKAMURA, T., HIRASHIMA, M., URASHIMA, T., OKA, T., FUTAI, M., MULLER, W. E., YAGI, F., KASAI, K. (2002), Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572: 232-254.
12. HOLÍKOVÁ, Z., HRDLICKOVÁ-CELA, E., PLZÁK, J., SMETANA, K. JR, BETKA, J., DVORÁNKOVÁ, B., ESNER, M., WASANO, K., ANDRÉ, S., KALTNER, H., MOTLÍK, J., HERCOGOVÁ, J., KODET, R., GABIUS, H. J. (2002). Defining the glycophenotype of squamous epithelia using plant and mammalian lectins. Differentiation-dependent expression of alpha2,6-and alpha2,3-linked N-acetylneuraminic acid in squamous epithelia and carcinomas, and its differential effect on binding of the endogenous lectins galectins-1 and-3. APMIS 110: 845-856.
13. JONCKHEERE, N., VAN, SEUNINGEN, I. (2008). The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit Rev Oncog 14: 177-196.
14. KLIJN, J. G., BERNS, P. M., SCHMITZ, P. M., FOEKENS, J. A. (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 13-17.
15. KUFE, D. W. (2009). Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9: 874-885.
16. LI, Y., REN, J., YU, W-H., LI, G., KUWAHARA, H., YIN, L., CARRAWAY, K. L. AND KUFE, D. (2001). The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and b-catenin. J Biol Chem 276: 35239-35242.
17. LIU, F. T. AND RABINOVICH, G. A. (2005). Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41.
18. MARCOS, N. T., PINHO, S., GRANDELA, C., CRUZ, A., SAMYN-PETIT, B., HARDUIN-LEPERS, A., ALMEIDA, R., SILVA, F., MORAIS, V., COSTA, J., KIHLBERG, J., CLAUSEN, H., REIS, C. A. (2004). Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 64: 7050-7057.
19. MATOS, A. J., LOPES, C., CARVALHEIRA, J., SANTOS, M., RUTTEMAN, G. R., GÄRTNER, F. (2006). E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables. J Comp Pathol 134: 182-189.
20. de MELO, F. H., BUTERA, D., MEDEIROS, R. S., ANDRADE, L. N., NONOGAKI, S., SOARES, F. A., ALVAREZ, R. A., MOURA DA SILVA, A. M., CHAMMAS, R. (2007). Biological applications of a chimeric probe for the assessment of galectin-3 ligands. J Histochem Cytochem 55: 1015-1026.
21. MENGWASSER, J., LIU, F. T., SLEEMAN, J. P. 2002. Galectin-3 is strongly up-regulated in nonapoptosing mammary epithelial cells during rat mammary gland involution. Glycobiology 12: 129-134.
22. MERLIN, J., STECHLY, L., DE BEAUCÉ, S., MONTÉ, D., LETEURTRE, E., VAN SEUNINGEN, I., HUET, G., PIGNY, P. (2011). Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene.
23. MIYAGI, T., WADA, T., YAMAGUCHI, K., SHIOZAKI, K., SATO, I., KAKUGAWA, Y., YAMANAMI, H., FUJIYA, T. (2008). Human sialidase as a cancer marker. Proteomics 8: 3303-3311.
24. NANGIA-MAKKER, P., HONJO, Y., SARVIS, R., AKAHANI, S., HOGAN, V., PIENTA, K. J., RAZ, A. (2000). Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156: 899-909.
25. NEDER, L., MARIE, S. K., CARLOTTI, C. G. JR., GABBAI, A. A., ROSEMBERG, S., MALHEIROS, S. M., SIQUEIRA, R. P., OBA-SHINJO, S. M., UNO, M., AGUIAR, P. H., MIURA, F., CHAMMAS, R. (2004). Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol 14: 399-405.
26. ORR, F. W., WANG, H. H. (2001). Tumor cell interactions with the microvasculature: a rate-limiting step in metastasis. Surg Oncol Clin N Am 10: 357-381.
27. OHTSUBO, K., MARTH, J. D. (2006). Glycosylation in cellular mechanisms of health and disease. Cell 126(5): 855-867.
28. de OLIVEIRA, J. T., DE MATOS, A. J. F., GOMES, J., VILANOVA, M., HESPANHOL, V., MANNINEN, A., RUTTEMAN, G., CHAMMAS, R., GÄRTNER, F., BERNARDES, E. S., (2010). Cordinated expression of galectin-3 and Galectins-3-binding sites in malignant mammary tumours: implications for tumour metastasis. Glycobiology 20: 1341-1352.
29. de OLIVEIRA, J. T., PINHO, S. S., DE MATOS, A. J., HESPANHOL, V., REIS, C. A., GÄRTNER, F. (2009). MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. Vet J 182: 491-493.
30. PAOLONI, M., KHANNA, C. (2008). Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156.
31. PICCO, G., JULIEN, S., BROCKHAUSEN, I., BEATSON, R., ANTONOPOULOS, A., HASLAM, S., MANDEL, U., DELL, A., PINDER, S., TAYLOR-PAPADIMITRIOU, J., BURCHELL, J. (2010). Over-expression of ST3Gal-I promotes mammary tumourigenesis. Glycobiology 20: 1241-1250.
32. PINHO, S. S., REIS, C. A., PAREDES, J., MAGALHÃES, A. M., FERREIRA, A. C., FIGUEIREDO, J., XIAOGANG, W., CARNEIRO, F., GÄRTNER, F., SERUCA, R. (2009). The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet 18: 2599-2608. (a)
33. PINHO, S. S., OSÓRIO, H., NITA-LAZAR, M., GOMES, J., LOPES, C., GÄRTNER, F., REIS, C. A. (2009). Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem Biophys Res Commun 379: 1091-1096. (b)
34. POWELL, L. D., WHITEHEART, S. W., HART, G. W. (1987). Cell surface sialic acid influences tumor cell recognition in the mixed lymphocyte reaction. J Immunol 139: 262-270.
35. RAMASAMY, S., DURAISAMY, S., BARBASHOV, S., KAWANO, T., KHARBANDA, S., KUFE, D. (2007). The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 27: 992-1004.
36. REIS, C. A., DAVID, L., SEIXAS, M., BURCHELL, J., SOBRINHO-SIMÕES, M. (1998). Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 79: 402-410.
37. RUTTEMAN, G. R., FOEKENS, J. A., PORTENGEN, H., VOS, J. H., BLANKENSTEIN, M. A., TESKE, E., CORNELISSE, C. J., MISDORP, W. (1994). Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Res Treat 30: 139-146.
38. SALOMON, D. S., BRANDT, R., CIARDIELLO, F., NORMANNO, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
39. SCHINDLBECK, C., STELLWAGEN, J., JESCHKE, U., KARSTEN, U., RACK, B., JANNI, W., JÜCKSTOCK, J., TULUSAN, A., SOMMER, H., FRIESE, K. (2008). Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis 25: 233-240.
40. SEKO, A., OHKURA, T., KITAMURA, H., YONEZAWA, S., SATO, E., YAMASHITA, K. (1996). Quantitative differences in GlcNAc:beta1>3 and GlcNAc:beta1>4 galactosyltransferase activities between human colonic adenocarcinomas and normal colonic mucosa. Cancer Res 56: 3468-3473.
41. SIPAUL, F., BIRCHALL, M., CORFIELD, A. 2011. What role do mucins have in the development of laryngeal squamous cell carcinoma? A systematic review. Eur Arch Otorhinolaryngol.
42. SÖDERBERG, O., GULLBERG, M., JARVIUS, M., RIDDERSTRÅLE, K., LEUCHOWIUS, K., JARVIUS, J., WESTER, K., HYDBRING, P., BAHRAM, F., LARSSON, L., LANDEGREN, U. (2006). Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Meth 3: 995-1000.
43. SÖNMEZ, H., SÜER, S., GÜNGÖR, Z., BALOGLU, H., KÖKOGLU, E. (1999), Tissue and serum sialidase levels in breast cancer. Cancer Lett 136: 75-78.
44. STORR, S. J., ROYLE, L., CHAPMAN, C. J., HAMID, U. M., ROBERTSON, J. F., MURRAY, A., DWEK, R. A., RUDD, P. M. (2008). The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 18: 456-462.
45. VLADIMIROVA, V., WAHA, A., LÜCKERATH, K., PESHEVA, P., PROBSTMEIER, R. (2008). Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J Neurosci Res 86: 2450-2461.
46. WANG, X., SCHNEIDER, A. (2010). HIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 31: 1202-1210.
47. WESSELING, J., VAN DER VALK, S. W., VOS, H. L., SONNENBERG, A., HILKENS, J. (1995). Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265.
48. YU, L. G., ANDREWS, N., ZHAO, Q., MCKEAN, D., WILLIAMS, J. F., CONNOR, L. J., GERASIMENKO, O. V., HILKENS, J., HIRABAYASHI, J., KASAI, K., RHODES, J. M. (2007). Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem 282: 773-781.
49. ZHAO, Q., GUO, X., NASH, G. B., STONE, P. C., HILKENS, J., RHODES, J. M., YU, L. G. (2009). Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 69: 6799-6806.
50. ZHAO, Q., BARCLAY, M., HILKENS, J., GUO, X., BARROW, H., RHODES, J. M., YU, L. G. (2010). Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer 9: 15.